NextCell Pharma AB (65G) AI Stock Analysis

NextCell Pharma AB

(Frankfurt:65G)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetThe absence of reported debt reduces refinancing pressure and interest-related financial risk, giving NextCell greater flexibility during development cycles. A debt-free structure can also preserve access to future financing options, although it does not offset the company’s current cash-burn challenges.

Negative Factors

Persistent cash burnSustained negative operating and free cash flow means the business is consuming cash rather than funding operations internally. This can require repeated capital raising or other financing, potentially limiting strategic flexibility and increasing dilution or funding pressure during ongoing clinical development.

NextCell Pharma AB (65G) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.65M
Dividend Yield: ―
Average Volume (3M): 2,700
Price to Earnings (P/E): -0.6
Beta (1Y): -0.35
Revenue Growth: 1.24%
EPS Growth: 32.46%
Country: Germany
Employees: 24
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

NextCell Pharma AB Business Overview & Revenue Model

Company Description

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investig...

NextCell Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:65G against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:FLUI	55Neutral	SEK 38.33M	13.65	21.37%	―	837.37%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:ANNX	42Neutral	SEK 57.89M	-1.51	―	―	―	7.33%
SE:XINT	39Underperform	SEK 134.36M	-2.67	245.07%	―	-38.46%	9.02%

* Healthcare Sector Average

Performance Comparison

DE:65G and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:65G	NextCell Pharma AB	0.01	-0.05	-78.69%
SE:XINT	Xintela AB	0.16	-0.25	-61.58%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.29	-55.33%
SE:IMMU	Immunicum AB	5.50	-1.90	-25.68%
SE:FLUI	Fluicell AB	27.90	15.10	117.97%
SE:ANNX	Annexin Pharmaceuticals AB	6.64	-19.56	-74.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

NextCell Pharma AB AI Stock Analysis